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Introduction: Individuals exposed both to cigarette smoke and respiratory pollu-
tants at work incur a greater risk of development of airway hyperresponsiveness
(AHR) and accelerated decline in forced expiratory volume in 1 s (FEV1) than that
incurred by subjects undergoing each exposure separately. We examined whether
smoking cessation or smoking reduction improves AHR and thereby slows down the
decline in FEV1 in occupationally exposed workers.
Methods: We examined 165 workers (137 males and 28 females) participating in a
smoking cessation programme. Nicotine tablets were used for smoking cessation or
smoking reduction. Respiratory symptoms were assessed by questionnaire, FEV1 by
spirometry and AHR by methacholine challenge test. At 1 year, subjects were
classified into quitters, reducers, or continuing smokers.
Results: Sixty-seven subjects completed the study (32 quitters; 17 reducers; 18
continuing smokers). Respiratory symptoms improved markedly in quitters (Po0:001
for all comparisons) and less so in reducers (P values between 0.163 and 0.027). At 1
year, FEV1 had slightly but significantly improved in quitters (P ¼ 0:006 vs. smokers;
P ¼ 0:038 vs. reducers) and markedly deteriorated in reducers and continuingElsevier Ltd. All rights reserved.
st for nicotine dependence; CO, carbon monoxide; MAC, methacholine airway challenge; AHR,
sted reciprocal dose response slope (DRS ¼ 1/[%fall FEV1/mmol+2.5]), FEV1, forced expiratory
ity
r Consumer Healthcare.
1, Faculte´ de Me´decine, B.P. 184-9, Av de la Foreˆt de Haye, 54505 Vandoeuvre-le`s-Nancy Cedex,
383 68 39 19.
@nancy.inserm.fr (A.B. Bohadana).
ARTICLE IN PRESS
A.B. Bohadana et al.1424smokers. Concurrent, 1-year change in AHR did not differ significantly among the
groups.
Conclusion: In occupationally exposed workers, stopping smoking markedly im-
proved respiratory symptoms and, in males, slowed the annual decline in FEV1.
Smoking reduction resulted in smaller improvements in symptoms but deterioration
in FEV1. These findings were independent of AHR. While smoking cessation should
remain the ultimate goal in workplace cessation programmes more studies are
necessary to better ascertain the benefits of smoking reduction.
& 2005 Elsevier Ltd. All rights reserved.Introduction
An association exists between cigarette smoking
and the development of airflow obstruction, with a
dose–response relationship between the amount of
tobacco smoked and both the level of obstruction
and an accelerated decline in forced expiratory
volume in 1 s (FEV1).
1,2 Occupational exposure—if
sufficiently intense or prolonged—may also inde-
pendently induce chronic airflow obstruction.3
Although the risk is smaller than with tobacco
smoking, it does affect a large proportion of the
population and its contribution to the ultimate
incidence of airflow obstruction is not negligible.
The development of airflow obstruction in
smokers and occupationally exposed individuals
seems to be correlated with the subject’s response
to non-specific airway challenge. Studies have
found airway hyperresponsiveness (AHR) to be a
predictor of progression of airflow obstruction both
in non-exposed smokers4 and workers in dusty
occupations.5,6
We therefore postulated that workers undergoing
exposure both to cigarette smoke and respiratory
pollutants at work incur a greater risk of develop-
ment of AHR and airflow obstruction than that
incurred by subjects undergoing each exposure
separately. For occupationally exposed smokers,
stopping smoking could be an important interven-
tion to reduce (or reverse?) AHR and, hopefully,
slow the decline in lung function. However, exis-
ting smoking cessation treatments only help moti-
vated smokers who are ready to quit; thus,
additional measures likely to reduce death or
illness such as smoking reduction should be given
consideration.7,8
As part of a smoking cessation programme
designed for occupationally exposed workers we
prospectively collected a large body of serial
methacholine responsiveness and lung function
data. Our aim was to investigate the 1-year im-
pact of smoking cessation or smoking reduction
on airway responsiveness and decline in lung
function.Methods
Subjects
The study enrolled occupationally exposed workers
(working in dusty occupations for X1 year) aged
18–65 years, who had smoked for 43 years and
were willing to quit or reduce smoking. All worked
in the Nancy area. Exclusion criteria included a
history of illness judged by the investigator likely to
influence the subject’s participation such as myo-
cardial infarction within the previous 3 months;
unstable angina; severe cardiac arrhythmia; preg-
nancy or breastfeeding; and use of nicotine
replacement during the previous 6 months. Workers
being treated for asthma or chronic obstructive
pulmonary disease (COPD) were not included but
referred to our outpatient clinic.
All subjects gave informed consent and the
study protocol was approved by the local ethics
committee.
Study, design and medication
The study was an open controlled exploratory
study. Eligible subjects were encouraged to quit
or, if unable, to reduce their smoking. They used
nicotine 2mg sublingual tablets ad libitum for 3
months. Highly dependent smokers (Fagerstro¨m
Test for Nicotine Dependence [FTND]9 score X6)
used 2 tablets/h; low-dependent smokers (FTND
score o6) used 1 tablet/h. The dose was tapered
off during months 4–6. No further use of nicotine
replacement was allowed during the 6 months follow-
up period to 1 year. All medications were supplied by
Pfizer Consumer Healthcare, Helsingborg, Sweden.
Assessments
Seven visits were arranged the day before quit-day
(Visit 1) and at 1 week (Visit 2), 2 weeks (Visit 3), 8
weeks (Visit 4), 12 weeks (Visit 5), 6 months (Visit
6), and 1 year (Visit 7) after quitting. At visit 1,
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sessed. A smoking history was obtained and the
carbon monoxide (CO) content of expired air was
measured using an EC50 Bedfont monitor (Technical
Instruments, Sittingbourne, England). Readings
were recorded in parts per million (ppm) of CO
(non-smokers o10 ppm; smokers 10–75 ppm).10
Pulmonary function was measured according to
the American Thoracic Society recommended stan-
dards.11 Spirometry was performed in the sitting
position with subjects expiring maximally into an
electronic spirometer (Minato, Autospiro AS-500)
after a maximal inspiratory manoeuver. At least 3
volume–time and flow–volume curves were ob-
tained and the forced vital capacity (FVC) and
the FEV1 calculated. These parameters were
expressed in absolute terms and as a percentage
of predicted.12
Methacholine airway challenge test13 was per-
formed at visits 1, 4, 6 and 7. After baseline
spirometry, the subject inhaled diluent (normal
saline), followed by spirometry. Subjects whose
baseline values were normal and whose FEV1 fell by
o10% after inhalation of diluent received three
cumulative doses of methacholine (0.4, 2.8 and
7.6 mmol, respectively) via a nebuliser delivering
particles 3 mm in diameter. Spirometry was per-
formed before and 3–5min after methacholine
inhalations. Subjects whose FEV1/FVC was p80%,
baseline FEV1p70%, or whose FEV1 fell by X10%
after saline, received an initial dose of methacho-
line of 0.2 mmol. The test was discontinued if the
FEV1 fell by X20% vs. baseline.
Methacholine responsiveness was analysed as
both a categorical and continuous variable. The
former was a fall in FEV1 equal to or greater than
20% (AHR+). The latter was the linear two-point
dose–response slope (DRS), calculated as the
percentage of fall of FEV1 at last dose divided
by the total dose of methacholine administered.14
A constant of +2.5 was added to all DRS values
and values were expressed as 1/slope+2.5 in order
to achieve approximate normality (Gaussian dis-
tribution) in a large number of non-exposed
subjects.13 The lower the value of this adjusted
reciprocal DRS the greater the airway responsive-
ness.
Respiratory symptoms were recorded using the
Respiratory Changes Questionnaire15 which evalu-
ates cough, phlegm, shortness of breath and
bronchitis, using the question: ‘‘How do you feel
now compared to 6 months ago?’’ Response options
were: 1 ¼ much worse, 2 ¼ worse, 3 ¼ no change,
4 ¼ better and 5 ¼ much better. The statistical
evaluation was performed on differences between
baseline and 1 year.Atopic status was measured at baseline by skin
prick test reaction to house dust, house dust mites,
animal danders, pollens, moulds, wheat, rye, oat,
and barley flours, and bakers’ yeast. A 9% codeine
phosphate solution and saline were used as positive
and negative controls. After 15min, wheal size was
recorded as the long axis and its perpendicular. A
test was positive if the mean wheal size at 15min
was X3mm.5 Atopy was defined as one or more
positive reactions.
Smoking status
Subjects were classified into: (1) ‘‘sustained quit-
ters’’ (complete abstinence at every visit; expired
CO o10 ppm); (2) ‘‘reducers’’ (reduction in cigar-
ette consumption vs. baseline; exhaled CO lower
than baseline after X6 h of active smoking); (3)
‘‘continuing smokers’’ (failure to decrease the
number of cigarettes compared with baseline).
Statistical analysis
Statistical analysis was carried out with the SAS
statistical software.16 Data were summarized using
means, standard deviations, and percentages.
Categorical variables were compared using the w2-
test or the Fisher exact test. For continuous
variables t-tests were used. At baseline, the
relationship between potential explanatory vari-
ables (age, sex, tobacco consumption, symptoms,
and atopy) and airway responsiveness (adjusted
reciprocal DRS) was assessed using multiple linear
regression analysis. Within-group analysis was
carried out examining the trend in change in
adjusted reciprocal DRS and FEV1 over time for
quitters, reducers and sustained smokers, and by
comparing the trend of each group vs. that of the
other groups by repeated measures ANOVA (RM
ANOVA).Results
Baseline characteristics
A total of 165 workers (75 bakers, 25 hairdressers,
14 woodworkers, 11 painters, and 40 miscellaneous
exposures) participated in the study. One male
subject refused to perform the methacholine
challenge testing at entry leaving 164 files for
analysis of responsiveness.
The baseline characteristics of the participants
are shown in Table 1. Workers completing the study
tended to be older, have lower CO levels and be less
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Table 1 Characteristics of exposed workers at inclusion.
Parameter All workers
(n ¼ 165)
Workers lost to
follow-up (n ¼ 97)
Workers
completing the
study (n ¼ 67)
P valuey
Demographics
Male/female 137/28 78/19 58/9 —
Age (years) 37.6 (9.1) 35.7 (8.7) 40.3 (9.1) 0.001
Height (cm) 173.1 (7.4) 173.1 (7.7) 173.0 (7.0) NS
Weight (kg) 74.6 (14.1) 74.7 (15.0) 74.1 (12.8) NS
Smoking history
FTND score 6.5 (2.1) 7.0 (2.0) 5.7 (1.9) 0.001
Carbon monoxide (ppm) 31.2 (10.5) 32.6 (10.5) 29.3 (10.4) 0.049
Pack/year 30.2 (17.8) 29.6 (18.5) 31.0 (16.9) NS
Symptoms
Cough 2.62 (0.66) 2.67 (0.62) 2.55 (0.70) NS
Phlegm 2.72 (0.57) 2.71 (0.56) 2.73 (0.59) NS
Shortness of breath 2.42 (0.65) 2.31 (0.68) 2.57 (0.58) NS
Bronchitis 2.82 (0.40) 2.79 (0.43) 2.85 (0.36) NS
Atopy yes, n (%) 45 (27%) 27 (28%) 18 (27%) NS
Pulmonary function tests
FEV1, % predicted 87.2 (12.5) 86.5 (12.2) 88.1 (12.9) NS
FVC, % predicted 94.1 (12.0) 92.9 (11.4) 95.8 (12.8) NS
FEV1/FVC % observed 77.4 (8.1) 78.1 (7.8) 76.4 (8.3) NS
Airway responsiveness
AHR+, yes (%)
Men 52 (38%) 28 (36%) 20 (34.5%) NS
Women 20 (71.5%) 14 (74%) 7 (78%) NS
P value 0.002 0.006 0.025
DRS
Men 0.217 (0.112) 0.225 (0.112) 0.207 (0.112) NS
Women 0.158 (0.090) 0.167 (0.099) 0.140 (0.078) NS
P value 0.010 0.071 0.089
FTND ¼ Fagerstro¨m test for nicotine dependence.
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; AHR+, positive methacholine airway challenge [fall in
FEV1420%]; DRS, adjusted reciprocal dose–response slope 1/[%fall FEV1/mmol+2.5].
The italic values concern the P values for VERTICAL comparisons between men and women.
One male subject refused to perform methacholine challenge testing.
yFor comparisons between workers having completed the study vs. workers lost to follow-up.
A.B. Bohadana et al.1426nicotine dependent than the workers lost to follow-
up. No significant differences between the two
groups were found in terms of symptoms, atopy,
lung function and airway responsiveness. However,
analysis by gender found women to be more
hyperreactive than men in all groups; using the
adjusted reciprocal DRS the difference was sig-
nificant only for the group as a whole.
The relative contribution of potential variables
for DRS was assessed in the group as a whole
by multiple linear regression analysis (con-
stant ¼ 0.111; R2 ¼ 0:21). Baseline FEV1
(coefficient ¼ 0.0034; SE ¼ 0.006; Po0:001) andfemale gender (coefficient ¼ 0.0752; SE ¼ 0.0210;
Po0:001) were the only variables correlated with
DRS; the presence of bronchitis was of borderline
significance (coefficient ¼ 0.0386; SE ¼ 0.0196;
P ¼ 0:051).Impact of smoking status on symptoms, lung
function and airway responsiveness
Sixty-seven subjects (40.6% of total) completed the
study. Of these 32 (19.4% of total) were sustained
quitters; 17 (10.3% of total) had reduced smoking
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Smoking cessation or reduction in occupationally exposed workers 1427by 50% or more and 18 (10.9% of total) were
continuing smokers.
The impact of smoking status on symptoms is
shown in Table 2. Smoking cessation improved
symptoms markedly, while smoking reduction im-
proved all symptoms but phlegm. No change was
noticed in symptom scores among continuing
smokers.
Table 3 shows the impact of smoking intervention
on FEV1 and DRS. Six male participants refused to
perform the challenge test thus leaving 61 files for
analysis (29 bakers, 10 hairdressers, 5 painters, 4
printers, 4 woodworkers, and 9 in miscellaneous
occupations). From the 61 remnants 31 were
quitters, 17 reducers and 13 continuing smokers.
At 1 year, a slight improvement was found in FEV1
among quitters and a marked deterioration among
reducers and continuing smokers. Using RM ANOVA
the differences were significant only for compar-
isons between quitters and reducers (P ¼ 0:038) or
smokers (P ¼ 0:006).
Concurrent changes in the adjusted reciprocal
DRS showed a slight improvement in quitters and
reducers but an aggravation in continuing smokers
but the differences among the various groups were
not significant. Incidentally, changes of borderline
significance were seen for comparisons between
smokers and the other groups.Discussion
This study showed that in occupationally exposed
workers smoking cessation markedly improved
symptoms and slightly improved the annual decline
in FEV1; reducing smoking resulted in smaller
improvements in symptoms but deterioration in
FEV1. In addition, the study found that the 1-year
change in FEV1 was not modulated by airway
responsiveness.
The improvement in respiratory symptoms in
quitters was not surprising. Although no similar
data are available for comparison, this finding is in
line with cross-sectional studies in the general
population showing lower prevalence rates of
symptoms in ex-smokers compared with smokers17
and with longitudinal studies showing that most
intermittent symptoms decrease fairly rapidly after
smoking cessation.18
Smoking reduction resulted in smaller improve-
ments in symptoms. Once again, data from working
populations are not available for comparison. An
anecdotal report of a patient with COPD found an
improvement in symptoms after drastic smoking
reduction.19 In a case study (n ¼ 17) all five
ARTICLE IN PRESS
Table 3 Lung function and airway responsiveness at inclusion and 1 year in occupationally exposed workers
(n ¼ 61) stratified by smoking status, plus smoking characteristics at inclusion.
Parameter Quitters n ¼ 31 (SD) Reducers n ¼ 17 (SD) Smokers n ¼ 13 (SD)
FEV1 Baseline survey
 87.2 (12.3) 87.5 (14.0) 88.4 (14.9)
Eight weeks 0.09 (0.29) 0.04 (0.23) 0.04 (0.23)
Six months 0.01 (0.33) 0.004 (0.32) 0.15 (0.18)
One year 0.04 (0.31) 0.14 (0.27) 0.16 (0.24)
P valuey Quitters vs. — P ¼ 0.038 P ¼ 0.006
Reducers vs. — — P ¼ 0.554
DRS Baseline survey 0.209 (0.128) 0.195 (0.088) 0.176(0.093)
Eight weeks 0.005 (0.075) 0.020 (0.057) 0.024 (0.088)
Six months 0.002 (0.082) 0.030 (0.077) 0.015 (0.048)
One year 0.012 (0.079) 0.036 (0.107) 0.012 (0.056)
P valuey Quitters vs. — P ¼ 0.531 P ¼ 0.053
Reducers vs. — — P ¼ 0.057
FTND at inclusion 5.4 (1.8) 6.0 (1.9) 5.7 (2.2)
Pack years at inclusion 29.8 (19.7) 28.3(12.0) 35.0 (16.9)
DRS: adjusted reciprocal dose–response slope ¼ 1/[%fall FEV1/mmol+2.5]; FEV1 ¼ forced expiratory volume in 1 s; FTND ¼ Fa-
gerstro¨m test for nicotine dependence.
Percent predicted.
yBy repeated measures ANOVA (RM ANOVA).
A.B. Bohadana et al.1428patients with airflow obstruction who could main-
tain a substantial reduction (from 30 to 6 cigarettes
a day) for 18 months showed improved symptoms
(and lung function).20 In our study, 13 of 17
reducers were able to cut their cigarette consump-
tion by 50% or more, which probably have improved
symptoms through a decrease in airway inflamma-
tion.21 The less pronounced improvement of symp-
toms in reducers is in line with data from the
general population7 and asthmatics.8
There was a positive effect of smoking cessation
on lung function, with quitters showing a slight
increase in FEV1 at end-study. Although small in
absolute terms (40mL) such improvement is
clinically important as it causes an upward shift
of FEV1 decline with ageing thus contributing to
prevent airway disability. Moreover, this improve-
ment in FEV1 in quitters contrasted with the
marked deterioration in reducers and continuing
smokers. This beneficial effect of smoking cessation
in workers undergoing occupational exposure has
not been reported previously; it suggests that for
ordinary levels of exposure the adverse respiratory
effects of smoking outweigh those of occupational
pollutants.
The improvement in FEV1 in quitters and its
deterioration in reducers and continuing smokers
was not modulated by airway responsiveness (Table
3, lower panel). This was rather surprising given thewell-known relation between baseline airway
calibre and airway responsiveness documented
previously in the general population22 and occu-
pationally exposed workers.13
How to interpret this discrepancy? One possible
explanation is the greater intrasubject variability
in measures of responsiveness compared with FEV1.
Another possibility is that, although closely linked,
the level of airway obstruction and the occurrence
of increased responsiveness are separate phenom-
ena. This idea is not new. In the Lung Health
Study23 part of the benefit from smoking cessation
on the change in AHR could not be accounted for by
the beneficial effect on the decline in FEV1. In an
earlier study, Kraan and colleagues24 treated
patients with allergic asthma with inhaled budeso-
nide and noted a maximal improvement in FEV1
within 2 weeks, while the airway responsiveness
also improved but only several weeks later; they
concluded that the improvement in AHR was not
only due to a change in airway calibre. We
speculate that this factor might have played a role
in our results as baseline FEV1 explained only 21% of
the variability of DRS (see Results).
This study has potential limitations. First, the
sample size at end-study was small. However,
numerous would-be participants were unable to
enrol due to working constraints; in addition, there
was a high dropout rate as is common in cessation
ARTICLE IN PRESS
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reducers and continuing smokers were sufficient for
us to note a significant change in symptoms and
FEV1. These results are strengthened by our
inclusion of young smokers since in slightly affected
or unaffected subjects there is virtually no room for
improvement. Second, the period of observation
was relatively small. However, since cigarette
smoking is deleterious for the lungs, a longer
observation period could only aggravate symptoms
and the annual decline in FEV1 in smokers, thus
rendering the difference with respect to quitters
even more significant. Finally, the exposure was
heterogeneous in nature. However, all substances
involved are likely to cause airway inflammation
and airflow obstruction.3 Incidentally, although no
environmental assessments could be performed
(the subjects worked in shops scattered over a
large area), the working conditions remained stable
throughout follow-up making it unlikely that the
improvement in symptoms and lung function in
quitters was due to changes in exposure.
In conclusion, this study documented the bene-
ficial effect of smoking cessation on symptoms
and decline in FEV1 in workers undergoing work-
place exposure to respiratory pollutants. A less
marked effect on symptoms was also noted in
reducers. Further, the study showed that the 1-year
change in lung function was not modulated by
AHR, suggesting that airway calibre might not be
the only determinant of airway responsiveness.
Finally, the study highlights the need to better
ascertain the benefits of smoking reduction as this
approach might act as a gateway to complete
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